There is no single patient-reported instrument that was developed specifically to assess symptoms and bladder-related consequences for neurogenic bladder dysfunction. The purpose of this study was to identify and consolidate items for a novel measurement tool for this population. Methods: Item generation was based on a literature review of existing instruments, open-ended semistructured interviews with patients, and expert opinion. Judgment-based item reduction was performed by a multidisciplinary expert group. The proposed questionnaire was sent to external experts for review. Results: Eight neurogenic quality of life measures and 29 urinary symptom-specific instruments were identified. From these, 266 relevant items were extracted and used in the creation of the new neurogenic symptom score. Qualitative interviews with 16 adult patients with neurogenic bladder dysfunction as a result of spinal cord injury, multiple sclerosis, or spina bifida were completed. Dominant themes included urinary incontinence, urinary tract infections, urgency, and bladder spasms. Using the literature review and interview data, 25 proposed items were reviewed by 12 external experts, and the questions evaluated based on importance on a scale of 1 (not important) to 5 (very important). Retained question domains had high mean importance ratings of 3.1 to 4.3 and good agreement with answer hierarchy. Conclusion: The proposed neurogenic bladder symptom score is a novel patient-reported outcome measure. Further work is underway to perform a data-based item reduction and to assess the validity and reliability of this instrument.
Introduction
Neurogenic bladder dysfunction can occur with any disease or lesion that affects the nervous system, such as spinal cord injuries (SCI), multiple sclerosis (MS), or spina bifida (SB). 1 Complications associated with neurogenic bladder dysfunction can cause significant morbidity and potential mortality, and the symptoms of neurogenic bladder dysfunction have been associated with a poor quality of life (QOL) among SCI, 2 MS, 3 and SB 4 patients. The level and completeness of the SCI dictate the occurrence of detrusor sphincter dyssynergia and neurogenic detrusor overactivity. 5 About 75% of patients with MS are estimated to have neurogenic bladder dysfunction 6 with symptoms such as incontinence (50%), retention (25%), and overactive bladder symptoms. 7 SB patients often have lifelong, complex neurogenic bladder issues that may require submit your manuscript | www.dovepress.com
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Welk et al surgical reconstruction. 1 The urologic assessment of these patients is complex. There are multiple symptoms (such as urinary incontinence, frequency, urgency, and obstruction) and complications (such as urinary tract infections, urinary stone disease, and renal dysfunction) that may be present, and patients may be managed with a variety of medications, devices (such as intermittent or indwelling catheters), and surgical procedures.
There is currently no patient-reported outcome measure (PROM) available to quantify the relevant urinary symptoms and complications in this population. For example, many studies evaluating intravesical onabotulinum toxin among patients with neurogenic detrusor overactivity have used PROMs created to measure urinary incontinence in the general population 8 rather than an instrument designed specifically for neurogenic bladder patients. A measurement tool for bladder-related QOL among patients with neurogenic bladder dysfunction has been developed; 9 however, health related QOL focuses on the psychosocial and functional impacts of a condition rather than on the more objective and quantifiable clinical symptoms and consequences of a condition.
Our objective is to develop a patient-reported neurogenic bladder symptom score (NBSS). The NBSS is based on the theory that there is a set of related neurogenic bladder specific symptoms and clinical consequences common to adult SCI, MS, and SB patients (Table 1) ; our goal is to create a measurement tool that will be able to discriminate among patients with different levels of bladder symptoms and that it will be evaluative (responsive to change after an intervention).
Materials and methods
The development of a new measurement tool consists of three stages: item generation, item reduction (using both judgment and data-based methods), and reliability and validity testing ( Figure 1) . 10 This study describes the results of the item generation and judgment-based item reduction using the following sequential steps. A review of the English literature was performed using Medline, ProQuest, PsychINFO, and Scopus databases. All English language, general QOL measures for SCI, MS, and SB were retrieved using a series of Medical Subject Heading (MeSH) terms and keywords ("quality of life", "questionnaires", "spinal dysraphism", "spinal cord injuries", "multiple sclerosis"). Previous questionnaires developed for the assessment of urinary symptoms were also identified using MeSH terms and keywords ("urinary incontinence", "prostate hyperplasia", "urination", "questionnaires", "quality of life"). Only questionnaires with a formal development process (consisting of a study reporting reliability and validity) were included. The references of identified studies were reviewed to identify additional questionnaires. Relevant questions and responses were extracted and categorized using NVivo 10 (QRS International, Doncaster, VIC, Australia). NVivo software facilitates the qualitative review of patient interview content and surveys based on common themes and words.
Patient interviews
The symptoms and consequences of neurogenic bladder dysfunction were further explored using qualitative, semistructured interviews conducted among patients with SCI, MS, or SB. We utilized a standardized, open-ended questioning technique, 10 with questions relating to bladder symptoms as well as specific probes into known symptoms and complications. Sample size was based on data redundancy (the point at which no new concepts were being generated). Responses were transcribed, and thematic analysis was conducted by two of the authors independently using the NVivo software to code relevant themes and keywords.
expert opinion
A multidisciplinary expert working group consisting of a urologist (with specialization in neurogenic bladder dysfunction), a neurologist (with specialization in MS), and physical medicine and rehabilitation physicians (with specialization in SCI), was assembled. Symptoms and complications of neurogenic bladder dysfunction were reviewed, and a comprehensive potential item list was generated based on data from the literature review and patient interviews. This proposed list of items was sent to multidisciplinary content experts across Canada for feedback and assessment of content validity. 11 Experts were asked to rate the importance of the proposed questions in relation to neurogenic bladder (on a scale of 1 [not important] to 5 [very important]), their agreement with the hierarchy of the answers (on a scale of 1 [no hierarchy] to 5 [good hierarchy]), and asked to add any additional relevant comments. The prespecified criteria for item-retention was a mean importance rating, and a mean agreement with hierarchy greater than 3.
Patient pretesting
The 25 revised questions were pretested on five patients with a SCI or MS to evaluate their interpretation, readability, and clarity as well as the completeness of the response choices. Questions were checked with the Question Understanding Aid 12 to identify possible correctable problems.
Results
Our literature review did not identify any existing instruments that were developed to measure neurogenic bladder symptoms. Measurement instruments found in the literature were classified as neurogenic disease specific QOL scales (eg, a SCI-specific QOL scale), or symptom-specific scales (eg, an overactive bladder symptom scale).
A total of nine neurogenic disease-specific (MS, SCI, or SB) QOL measures were identified, which had items about neurogenic bladder dysfunction (Table 2) . Specific questions related to urinary function were limited to the impact of urinating on social, physical, and emotional domains as well as specific symptoms, such as urinary incontinence, frequency, and urgency. A publication addressing the qualitative development of a SCI-specific QOL instrument confirmed that bladder issues were a common problem within the physical medicine domain. 13 The Qualiveen 9 is a urinary specific QOL measure with domains of limitations, constraints, fears, and feelings; these domains contain a mix of physical, social, and emotional issues related to bladder dysfunction. The SCI-Secondary Complications Scale 14 included two relevant questions about the prevalence of "bladder dysfunction" and urinary infections over a 3-month time course. The International SCI Data set for Lower Urinary Tract Function is not a PROM; however, it does include important standardized demographic and bladder management questions. 15 A total of 29 urinary symptom-specific measurement tools were identified ( Table 3 ). The majority of questionnaires were developed for female urinary incontinence (and included both symptom indexes as well as incontinencerelated QOL indexes), male voiding symptoms (generally referred to as prostate symptom scores), and a few questionnaires for specific aspects of urinary symptoms, such as nocturia or urinary urgency. The individual questions were submit your manuscript | www.dovepress.com
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Condition Questions
Female/general urinary incontinence The multidisciplinary group reduced the item pool using a judgment-based approach. Questions that were duplicates, not relevant to neurogenic bladder patients, or not related to specific bladder symptoms or complications were eliminated. The remaining questions were used in the creation of potential items for the NBSS. The items were modified to ensure they were applicable to patients with indwelling catheters, intermittent catheters, and urinary diversions. An adjectival scale was used for the items, with a total of four or five ordinal response options. A single categorical question was included to determine the method of bladder management.
Interviews were conducted with 16 adult patients. This was a diverse group of patients with a variety of ages, impairment levels, device use, and previous urologic surgery; Research 
133
a patient-reported neurogenic bladder symptom score demographic details for the SCI and MS patients are presented in Table 4 . The interviews suggested that urinary incontinence, urinary tract infections, urgency, and bladder spasms were dominant issues that were relevant to the majority of patients. The dimensions and components outlined in Table 1 adequately covered all relevant concepts identified during the interviews.
A total of 25 questions (14 on symptoms, seven on complications, and four on urinary-related QOL) were included for review by external content experts (Table S1 ). An electronic survey was sent to 19 experts, of whom 12 responded (63%; eight urologists, three SCI physiatrists, one neurologist). A total of five questions were eliminated because of perceived redundancy or low importance rating, and five new questions were added based on their feedback (Table 5) . No questions were eliminated because of poor answer hierarchy.
During patient pretesting, small changes were made where necessary in the questions and wording to improve interpretation of the items. The Question Understanding Aid 12 tool identified minor issues, which in most cases were easily corrected. Some issues such as the use of "unfamiliar technical terms" (eg, the words urinary, bladder, or catheter) were unavoidable, and we found they were adequately understood in this population.
Discussion
PROMs provide a more interpretable and scientifically meaningful measurement than unvalidated patient interviews or questionnaires, and they allow standardization and comparability between studies; they have become an important endpoint for clinical trials and therapeutic interventions. There is, however, little research and development done on clinical measurement tools for neurogenic bladder patients. Investigators have often been forced to rely on unvalidated or inappropriate instruments to evaluate the neurogenic bladder population. 2 There are instruments for QOL measurement for specific populations, such as the Quality of Life Profile for Adults with Physical Disabilities 16 or the Multiple Sclerosis Quality of Life-54; 3 however, these instruments have only a very limited inclusion of items related to neurogenic bladder, making them impractical for many urologic applications. The Qualiveen 9 was developed to measure urinary-related QOL among SCI patients. While QOL is an important concept, it is not the primary measurement goal of the NBSS. QOL is an abstract concept, usually based on social, functional, and emotional domains. This concept does not allow a clinician or investigator to assess specific clinical domains or relate changes to specific clinical parameters. An intervention may not improve a patient's QOL, however it may significantly change their bladder symptoms. For example, the commonly used American Urology Association Symptom Score 17 measures male lower urinary tract symptoms. A separate QOL question assesses the impact of those symptoms. These two sections are complementary and do not necessary correlate: severe symptoms can have no impact on a person's QOL, and some patients rate their QOL as poor despite only mild symptoms. The primary goal of the NBSS is to measure neurogenic bladder symptom domains, which is distinct and complementary to urinary related QOL.
The creation of a specific instrument that is designed and validated for symptom assessment among neurogenic bladder patients is a considerable challenge given the spectrum of urinary symptoms and impairments, general mobility restrictions, differing functional abilities, possible catheter usage, and previous urinary reconstructive surgery. For example, many studies have focused on the continence of neurogenic bladder patients. The Incontinence-QOL instrument 18 was developed to assess female stress and urgency incontinence and was then validated in the neurogenic bladder population. 19 While the Incontinence-QOL covers issues relevant to general incontinence, it does not address the other important areas of neurogenic bladder dysfunction, such as urinary infection or catheter bypassing. In addition, it includes questions that are not relevant to many neurogenic bladder patients, such as "I have to be careful about standing up after sitting down." submit your manuscript | www.dovepress.com
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Welk et al SCI, MS, and SB patients are a diverse group, that are often assembled into a single cohort for studies of urologic interventions, such as oral anticholinergic therapy, intravesical onabotulinum toxin, bladder augmentation, or urinary diversion. 1 The NBSS will assess these interventions with a single PROM that could be used for patients with catheters, urinary diversions, or spontaneous voiding. Moreover, by focusing on symptoms, the domains are easy to conceptualize and understand and may be used to measure specific clinical changes in a simple and efficient manner. The proposed domain structure of the NBSS will also allow clinicians to look at specific subscales, for example urinary incontinence, if that is their primary interest. In addition, domains which are frequently not measured in PROMs, such as stone disease and medication side effects, are included.
The strengths of the development process so far include a multidisciplinary approach to generating potential items for the NBSS. We believe the steps we have taken thus far, and the external expert review, demonstrate an acceptable face validity for the NBSS. Items have been designed to be potentially responsive to interventions aimed at treating symptoms or consequences of neurogenic bladder dysfunction. Potential limitations of our development process include a single language (English) and cultural setting (Canada), which may limit future international generalizability. While we strove to maximize generalizability, some domains could not be included. For example, renal failure and autonomic dysreflexia are two topics we felt we could not adequately address using a PROM given the complexity and specific medical facts that would be necessary to meaningfully assess these area. Further study is currently underway to examine the domain structure (Table 1) , with factor analysis, and to establish the construct validity and reliability of the NBSS.
Conclusion
This paper summarizes the initial steps in the development of a NBSS. Using the available literature, patient interviews, and expert opinion, a 25-item questionnaire has been created to assess bladder symptoms and consequences among neurogenic bladder patients. The methods undertaken thus far, and the results of the external review by content experts, demonstrate the face and content validity of the NBSS. Additional study is underway to assess the measurement properties of the NBSS.
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